Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00774852 · ClinicalTrials.gov registry record · Phase 2
Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 137
- Enrollment target
NCT00774852 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 137 participants.
The verdict
NCT00774852, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 137 participants
- Enrollment target
Study Summary
This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophosphamide therapy by itself.
Interventions
- DRUG prednisone
- DRUG cyclophosphamide
- DRUG abatacept
- DRUG azathioprine
- DRUG abatacept placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 137 participants |
| Start Date | 2008-11 |
| Est. Completion | 2014-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00774852
The ClinicalTrials.gov registry entry for NCT00774852 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 137 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00774852 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00774852 about?
NCT00774852 is a clinical study titled "Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis". This study is for individuals with lupus who have developed complications in their kidneys, or lupus nephritis. The study will determine whether adding the experimental medication abatacept to standard cyclophosphamide therapy is more effective in improving lupus nephritis than standard cyclophospha...
What is the current status of trial NCT00774852?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 137 participants. The study started on 2008-11. Estimated completion is 2014-06.
What interventions are being tested in trial NCT00774852?
The interventions under investigation include: prednisone (DRUG), cyclophosphamide (DRUG), abatacept (DRUG), azathioprine (DRUG), abatacept placebo (DRUG).
Who is sponsoring clinical trial NCT00774852?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.